Omecent 40 mg (Capsule (Enteric Coated))
Unit Price: ৳ 8.00 (3 x 10: ৳ 240.00)
Strip Price: ৳ 80.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Omeprazole |
| Company | Centeon pharma ltd |
| Also available as |
Indications
- Gastric and duodenal ulcer
- NSAID-associated duodenal and gastric ulcer
- Prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
- Gastro-esophageal reflux disease
- Long-term management of acid reflux disease
- Acid-related dyspepsia
- Severe ulcerating reflux esophagitis
- Prophylaxis of acid aspiration during general anesthesia
- Zollinger-Ellison syndrome
- Helicobacter pylori-induced peptic ulcer
Pharmacology
- Inhibitor of gastric acid secretion
- Blocks hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system
- Onset of the antisecretory effect occurs within one hour
- Maximum effect occurs within two hours
- Inhibition of secretion lasts up to 72 hours
- Secretory activity returns gradually over 3 to 5 days after discontinuation
Dosage
- Dosage for benign gastric and duodenal ulcer
- Dosage for NSAID-associated duodenal or gastric ulcer
- Dosage for gastro-esophageal reflux disease
- Long-term management dosage of acid reflux disease
- Dosage for acid-related dyspepsia
- Dosage for prophylaxis of acid aspiration
- Dosage for Zollinger-Ellison syndrome
- Dose for Helicobacter pylori eradication regimen
- Paediatric use in severe ulcerating reflux esophagitis
Administration
- Direction for use of IV Injection
- Direction for use of IV Infusion
- Intravenous administration only
- IV injection should be given slowly
- IV infusion should be given over a period of 20-30 minutes or more
- Reconstituted solution should not be mixed or co-administered with any other drug
- Freshly prepared solution should be used within a specific timeframe
Interaction
- Decreased intragastric acidity affecting the absorption of other drugs
- Metabolism through cytochrome P450 delaying the elimination of other drugs
- Recommendation to monitor patients receiving warfarin or phenytoin
- Plasma concentrations of Omeprazole and clarithromycin increased during concomitant administration
- No evidence of interaction with specific drugs (phenacetin, theophylline, caffeine, etc.)
- Simultaneous treatment with digoxin leads to a 10% increase in the bioavailability of digoxin
Contraindications
- Contraindicated in patients with known hypersensitivity to omeprazole
- Exclusion of malignancy in suspected cases of gastric ulcer before treatment initiation
Side Effects
- Well tolerated with generally mild and reversible adverse reactions
- Reported skin rash, urticaria, and pruritus
- Photosensitivity, bullous eruption, and erythema multiforme reported in isolated cases
- Diarrhea and headache reported
- Gastrointestinal reactions like constipation, nausea/vomiting, flatulence, and abdominal pain
- Dizziness, light-headedness, and feeling faint associated with treatment
- Reversible mental confusion, agitation, depression, and hallucinations reported predominantly in severely ill patients
- Arthritic and myalgic symptoms reported
Pregnancy & Lactation
- No adverse effects on pregnancy or the health of the fetus/newborn child in prospective epidemiological studies
- Omeprazole can be used during pregnancy
- No information available on the passage of Omeprazole into breast milk or its effects on the neonate
- Discontinuation of breastfeeding if the use of Omeprazole is considered essential
- Safety and effectiveness not established in pediatric patients less than 18 years of age
Precautions & Warnings
- Avoid concomitant use of clopidogrel and omeprazole
- Observational studies suggest increased risk for osteoporosis-related fractures with PPI therapy
- Atrophic gastritis noted occasionally in gastric corpus biopsies from long-term treated patients
- Concomitant use with methotrexate may lead to methotrexate toxicities
Therapeutic Class
- Proton Pump Inhibitor
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children